Δημοσίευση στις 2019 Dec 16 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/31841131/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=11
Renata Cífková
, Mark R Johnson
, Thomas Kahan
, Jana Brguljan
, Bryan Williams
, Antonio Coca
, Athanasios Manolis
, Costas Thomopoulos
, Claudio Borghi
0
, Costas Tsioufis
, Gianfranco Parati
, Isabella Sudano
, Richard J McManus
, Bert-Jan H van den Born
, Vera Regitz-Zagrosek
, Giovanni de Simone
[Online ahead of print]
Affiliations
Item in Clipboard
et al.
Eur Heart J Cardiovasc Pharmacother.
2019
Abstract
Hypertensive disorders are the most common medical complications in the peripartum period associated with a substantial increase in morbidity and mortality. Hypertension in the peripartum period may be due to the continuation of pre-existing or gestational hypertension, de novo development of pre-eclampsia or it may be also induced by some drugs used for analgesia or suppression of postpartum haemorrhage. Women with severe hypertension and hypertensive emergencies are at high risk of life threatening complications, therefore, despite the lack of evidence-based data, based on expert opinion, antihypertensive treatment is recommended. Labetalol intravenously and metyldopa orally are then the two most frequently used drugs. Short-acting oral nifedipine is suggested to be used only if other drugs or iv access are not available. Induction of labour is associated with improved maternal outcome and should be advised for women with gestational hypertension or mild pre-eclampsia at 37 weeks᾽ gestation. This position paper provides the first interdisciplinary approach to the management of hypertension in the peripartum period based on the best available evidence and expert consensus.
Keywords:
antihypertensive drugs; gestational hypertension; hypertensive emergency; low dose of acetylsalicylic acid; pre-eclampsia; pre-existing hypertension.
© Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2019. For permissions, please email: [email protected]
Similar articles
-
Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial.
Lancet. 2009 Sep 19;374(9694):979-988. doi: 10.1016/S0140-6736(09)60736-4. Epub 2009 Aug 3.
Lancet. 2009.
PMID: 19656558Clinical Trial..
-
Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks’ gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial.
BMC Pregnancy Childbirth. 2011 Jul 7;11:50. doi: 10.1186/1471-2393-11-50.
BMC Pregnancy Childbirth. 2011.
PMID: 21736705
Free PMC article.Clinical Trial..
-
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
Lancet. 2019 Sep 21;394(10203):1011-1021. doi: 10.1016/S0140-6736(19)31282-6. Epub 2019 Aug 1.
Lancet. 2019.
PMID: 31378394
Free PMC article.Clinical Trial..
-
Severe pre-eclampsia and hypertensive crises.
Best Pract Res Clin Obstet Gynaecol. 2013 Dec;27(6):877-84. doi: 10.1016/j.bpobgyn.2013.07.003. Epub 2013 Aug 17.
Best Pract Res Clin Obstet Gynaecol. 2013.
PMID: 23962474Review..
-
Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.
CMAJ. 1997 Nov 1;157(9):1245-54.
CMAJ. 1997.
PMID: 9361646
Free PMC article.Review..